Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy

PharmacoEconomics

Volumn 28, Issue 11, 2010, Pages 1041-1054

  Eandi, Mario ^a   Pradelli, Lorenzo ^b   Iannazzo, Sergio ^b   Chiroli, Silvia ^c   Pontoriero, Giuseppe ^d  

^a UNIVERSITY OF TURIN   (Italy)

^b AdRes Health Economics and Outcomes Research   (Italy)

^c AMGEN INC   (United States)

^d A MANZONI HOSPITAL   (Italy)

Author keywords

Cinacalcet; Cost effectiveness; Cost utility; Phosphate binders; Secondary hyperparathyroidism; therapeutic use; treatment; Vitamin D analogues

Indexed keywords

ALFACALCIDOL; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CINACALCET; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; PHOSPHOROUS ACID; SEVELAMER; STEROL;

ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST UTILITY ANALYSIS; DIALYSIS; DRUG COST; DRUG EFFECT; ECONOMIC EVALUATION; HEALTH CARE COST; ITALY; LIFE EXPECTANCY; OPEN STUDY; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; SECONDARY HYPERPARATHYROIDISM;

ADULT; AGED; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DECISION TREES; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; ITALY; LIFE EXPECTANCY; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, STATISTICAL; NAPHTHALENES; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 77957987595     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11538600-000000000-00000     Document Type: Article

References (45)

1. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83
2. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO (4), Ca × PO (4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-8
3. London GM, Guerin AP, Verbeke FH, et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007;18:613-20
4. Krasniak A, Drozdz M, Pasowicz M, et al. Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrol Dial Transplant 2007;22:515-21
5. Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006;70:1358-66
6. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18
7. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005;67:1179-87
8. Eknoyan G, Levin A, Levin N. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42 Suppl 3: S1-201
9. Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:34-8
10. Locatelli F. The need for better control of secondary hyperparathyroidism. Nephrol Dial Transplant 2004;19 Suppl. 5: V15-9
11. Locatelli F, Limardo M, Pontoriero G. New approaches to treatment of secondary hyperparathyroidism. Curr Opin Investig Drugs 2008;9:363-70
12. Block GA, Martin KJ, de Francisco ALM, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25
13. Moe SM, Cunningham J, Bommer J, et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 2005;20:2186-93
14. Messa P, Macário F, Yaqoob M, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008;3:36-45
15. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; (113):S1-130
16. Chertow GM, Pupim LB, Block GA, et al. Evaluation of cinacalcet therapy to lower cardiovascular events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007;2:898-905
17. Cunningham J, Urena P, Reichel H, et al. Long-term (5-year) efficacy of cinacalcet in secondary hyperparathyroidism (HPT) of end stage renal disease (CKD STAGE 5) [abstract]. XLII ERA-EDTA Congress; 2005 Jun. 4-7; Istanbul
18. ISTAT: Italian National Institute of Statistics. Italian population life tables geographical area: Italia-males and females-year: 2005 [online]. Available from URL: http://www.demo.istat.it/unitav/index.html?lingua=eng [Accessed 2010 Jul. 27]
19. SIN-Italian Society for Nephrology. Registro Italiano di Dialisi e Trapianto. Report 2005 [online]. Available from URL: http://www.sin-ridt.org/ sin-ridt.org.htm [Accessed 2008 Jun. 26]
20. Covic A, Kothawala P, Bernal M, et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009;24:1506-23
21. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771-80
22. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005;16:1788-93
23. Trespalacios FC, Taylor AJ, Agodoa LY, et al. Heart failure as a cause for hospitalization in chronic dialysis patients. Am J Kidney Dis 2003;41:1267-77
24. Goldsmith D, Kothawala P, Chalian A, et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of fracture and need for parathyroidectomy in CKD. Am J Kidney Dis 2009;53:1002-13
25. Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of parathyroidectomy in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Hemodial Int 2007;11:62-71
26. Kestenbaum B, Andress DL, Schwartz SM, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int 2004;66:2010-6
27. de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy 1998;44:215-32
28. Nichol G, Kaul P, Huszti E, et al. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med 2004;141:343-51
29. Martin AJ, Glasziou PP, Simes RJ. A cardiovascular extension of the Health Measurement Questionnaire. J Epidemiol Community Health 1999;53:548-57
30. Nease RFJ, Kneeland T, O'Connor GT, et al. Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team. JAMA 1995;273:1185-90
31. Brazier JE, Green C, Kanis JA. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 2002;13:768-76
32. Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess 2007;11(18): iii, xi-xiii, 1-167
33. L'Informatore Farmaceutico. Italian directory of medicines and manufacturers. 69th Rev. Milan: Elsevier, 2009
34. Nomenclatore Tariffario Nazionale: DRG tariffs. DMS 2006 Sep. 12. Supplemento Ordinario alla Gazzetta Ufficiale 2006 Dec. 13; 289
35. Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68:1793-800
36. Eandi M, Giotta N, Santagostino Barbone G. Analisi costo/efficacia di sevelamer nel trattamento dell'iperfosforemia del paziente in dialisi. Farmeconomia e Percorsi Terapeutici 2004;5:201-18
37. Briggs A. Handling uncertainty in economic evaluations and presenting the results. In: Drummond M, McGuire A, editors. Economic evaluation in health care. Oxford: Oxford University Press; 2001:172-214
38. Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium phosphorus in secondary hyperparathyroidism. Kidney Int 2003;63:248-54
39. Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003;14:575-83
40. Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16:800-7
41. Block GA, Zaun D, Smits G, et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int. Epub 2010 Jun. 16
42. Fondazione Censis: I trattamenti sostitutivi della funzione renale in Italia: aspetti clinici, economici e sociali: Sintesi dei risultati. Rome, March 2009 [online]. Available from URL: http://www.censis.it/files/Ricerche/2009/ Sintesi-Funzione-Renale.pdf [Accessed 2009 Sep. 3]
43. Gincherman Y, Moloney K, McKee C, et al. Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients. Hemodial Int 2010 Jan; 14(1):68-72
44. Sabaté E. editor. Adherence to long term therapies: evidence for action. Geneva: WHO, 2003:212
45. Hughes D, Cowell W, Koncz T, et al. Methods for integrating medication compliance and persistence in Pharmacoeconomic Evaluations. Value Health 2007;10:498-509